Peripartum cardiomyopathy (PPCM) is an often fatal disease that affects pregnant women who are near delivery, and it occurs more frequently in women with pre-eclampsia and/or multiple gestation. The aetiology of PPCM, and why it is associated with pre-eclampsia, remain unknown. Here we show that PPCM is associated with a systemic angiogenic imbalance, accentuated by pre-eclampsia. Mice that lack cardiac PGC-1a, a powerful regulator of angiogenesis, develop profound PPCM. Importantly, the PPCM is entirely rescued by pro-angiogenic therapies. In humans, the placenta in late gestation secretes VEGF inhibitors like soluble FLT1 (sFLT1), and this is accentuated by multiple gestation and pre-eclampsia. This anti-angiogenic environment is accompanied by subclinical cardiac dysfunction, the extent of which correlates with circulating levels of sFLT1. Exogenous sFLT1 alone caused diastolic dysfunction in wild-type mice, and profound systolic dysfunction in mice lacking cardiac PGC-1a. Finally, plasma samples from women with PPCM contained abnormally high levels of sFLT1. These data indicate that PPCM is mainly a vascular disease, caused by excess anti-angiogenic signalling in the peripartum period. The data also explain how late pregnancy poses a threat to cardiac homeostasis, and why pre-eclampsia and multiple gestation are important risk factors for the development of PPCM.
PPCM affects 1 in 300 to 1 in 3,000 pregnancies, with geographic hot spots of high incidence, such as Nigeria and Haiti 1,2 . The disease is characterized by systolic heart failure presenting in the last month of pregnancy or the first 5 months post-partum. Although approximately half of affected women recover cardiac function post-partum, many patients progress to chronic heart failure, cardiac transplantation or death. Thus, PPCM can devastate otherwise healthy young women and their infants. PPCM remains a disease of unknown aetiology. The onset late in gestation does not coincide with increased haemodynamic load on the heart, suggesting that other mechanisms are responsible. Recent data have suggested that anti-angiogenic prolactin fragments may have an important role in causing the disease in some patients 3 . Risk factors for PPCM also include pre-eclampsia and multiple gestation, suggesting potential mechanistic overlap with these processes 1, 2 .
PGC-1a is a transcriptional coactivator that drives mitochondrial biogenesis and other metabolic programs in many tissues, including the heart 4, 5 . PGC-1a is highly expressed in the heart, and mice lacking PGC-1a globally have abnormal cardiac energetic reserves and respond poorly to stressful stimuli such as transverse aortic banding 6, 7 . In addition to its role in mitochondrial homeostasis, PGC-1a also induces the expression and secretion of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), which leads to formation of new blood vessels 8, 9 . Although the angiogenic function of PGC-1a has been described in skeletal muscle, its role in cardiac tissue remains unexplored.
Cardiac-specific PGC-1a deletion leads to PPCM
To study further the role of PGC-1a in the heart, we generated cardiac-specific PGC-1a knockout (HKO) mice (see Methods). While studying these mice, we noticed that female HKO mice were fertile, and delivered normal litter sizes (not shown), but invariably died after one or two pregnancies (Fig. 1a ). The hearts of these mice were large, dilated and fibrotic ( Fig. 1b-d) , consistent with a dilated cardiomyopathy. Twodimensional M-mode echocardiography revealed dilated, poorly contractile hearts in HKO mice after their second delivery ( Fig. 1e ). Left ventricular end-diastolic dimensions (LVEDD) and left ventricular endsystolic dimensions (LVESD) were markedly enlarged, and fractional shortening, a direct measure of cardiac contractile function, was profoundly depressed ( Fig. 1f -i). Nulliparous mice, as well as post-partum control mice, were not affected. Males were also not affected ( Supplementary Fig. 1 ). Thus, the absence of PGC-1a in cardiomyocytes leads to a profound PPCM in mice.
PGC-1a regulates angiogenesis in cardiac tissue
We have recently shown in skeletal muscle that PGC-1a regulates angiogenesis by driving the expression of angiogenic factors like VEGF 8, 9 . Anti-angiogenic therapies, including antibodies that neutralize VEGF and small-molecule VEGF receptor inhibitors, are increasingly being used in oncological and ophthalmological treatments, and cardiomyopathy and heart failure have recently been recognized as important side effects 10, 11 , showing that anti-angiogenic therapy can be harmful to the heart in humans. Impaired VEGF signalling has also been linked with cardiac dysfunction in mice 12, 13 . At the same time, late pregnancy is a strong anti-angiogenic environment, partly owing to the secretion by the placenta of anti-angiogenic factors, like sFLT1, that bind to and neutralize soluble members of the VEGF family 14 . These observations led us to postulate that PGC-1a regulates an angiogenic program in cardiomyocytes, and that the absence of this program would leave the hearts defenceless to the anti-angiogenic setting of late pregnancy, thus leading the animals to develop PPCM.
Consistent with this idea, overexpression of PGC-1a in neonatal rat ventricular myocytes (NRVMs) strongly induced angiogenic genes involved in the activation and recruitment of endothelial cells (for example, Vegfa) and mural cells (for example, Pdgfb), as well as genes that are involved in the mitochondrial respiratory chain 15 (for example, Cycs and Cox5b) ( Fig. 2a ). Interestingly, some angiogenic genes were repressed (for example, Bfgf), with a pattern of repression that is similar to that seen in skeletal muscle cells 8 , indicating that PGC-1a reprograms the angiogenic program in a stereotypical manner. Conversely, PGC-1a short interfering RNA (siPGC-1a) significantly suppressed the expression of Vegfa (Fig. 2b) . Endothelial activation and migration is a hallmark of angiogenesis. As shown in Fig. 2c , d, overexpression of PGC-1a in NRVMs led to a marked, dose-dependent, up to sixfold increase in the migration of the adjacent human umbilical vein endothelial cells (HUVECs) in a coculture system. Addition of sFLT1 completely neutralized the induced endothelial migration, indicating that secreted members of the VEGF family, probably VEGFA itself, are critical for the effect. Conversely, repression of PGC-1a in NRVMs by siRNA significantly repressed endothelial migration ( Fig. 2e ). Thus, PGC-1a controls an angiogenic program in cardiomyocytes.
To test whether PGC-1a is required for this program in intact animals, levels of Vegfa and other angiogenic factors were measured in hearts from PGC-1a HKO mice. The expression of Vegfa and Pdgfb, and a number of other angiogenic factors, was repressed in these hearts by as much as 50% ( Fig. 3a ). VEGFA protein was decreased by 30% in HKO hearts (Fig. 3b ). Levels of VEGFA are normally tightly regulated, and even global haplo-insufficiency is lethal 16, 17 , underscoring the significance of a 30% drop in protein levels. Consistent with these findings, the capillary density of HKO hearts, as measured by staining with the endothelial-specific marker CD31, was decreased by about 15% (Fig. 3c, d) . Thus, PGC-1a regulates both vascular density (these data) and mitochondrial function 18 in the heart, providing an important regulatory link between the delivery of fuel (through blood vessels) and its consumption (by mitochondria).These data suggest that PPCM in these mice might be caused by the combination of a heart-specific vascular defect caused by the absence of PGC-1a, and the normal systemic antiangiogenic environment of late pregnancy. Indeed, the vascular density in HKO hearts decreased by almost 50% post-partum ( Fig. 3c, d ), which is equivalent to the decrease in vascular density seen in mice lacking cardiac VEGF 19 . Consistent with this vascular rarefaction, perfusion of post-partum HKO hearts was profoundly decreased by nearly 50% compared to wild-type animals, as determined by methoxyisobutylisonitrile (MIBI) uptake and single-photon emission computed tomography and X-ray computed tomography (SPECT/CT) ( Fig. 3e , f).
Pro-angiogenic therapy rescues PPCM
To test directly the idea that an angiogenic imbalance drives PPCM in HKO mice, rescue experiments were carried out. In a first series of experiments, breeding mice were administered daily subcutaneous injections of VEGF121 protein (100 mg kg 21 ), an isoform of VEGFA, versus vehicle control ( Supplementary Fig. 2 ). The efficacy of VEGF121 injections was confirmed by the presence of VEGF121 in the serum, and robust activation of cardiac VEGFR2 phosphorylation within 30 min of injection ( Supplementary Fig. 2b, c) . The VEGF treatment led to improved survival of the breeding HKO females; they were able to survive up to five pregnancies ( Supplementary Fig. 2d ). However, capillary density was only partly rescued, cardiac contractility was only marginally improved and the hearts remained enlarged (Supplementary Fig. 2e -g). Thus, VEGF administration partly rescued lethality in multiparous HKO animals, but it was insufficient to fully rescue PPCM, suggesting that other pathways are also important.
It has recently been shown that STAT3 regulates mitochondrial superoxide dismutase (MNSOD) and protects against reactive oxygen species (ROS) in the heart 3 . Absence of cardiac STAT3 and the consequent increase in ROS led to inappropriate cleavage of prolactin to a potent anti-angiogenic 16-kDa form, and subsequent PPCM ( Fig. 4a ). Importantly, the PPCM could be rescued by treatment with bromocriptine, which inhibits the secretion of prolactin 
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from the pituitary gland. PGC-1a is known to increase ROS scavenging 20 . In cardiomyocytes, overexpression of PGC-1a strongly induced Mnsod mRNA and protein expression ( Supplementary  Fig. 3a, b ). Conversely, MNSOD was repressed in PGC-1a HKO hearts, and levels of ROS were increased ( Supplementary Fig. 3c, d) .
Thus, PGC-1a and STAT3 both regulate MNSOD and ROS in cardiomyocytes, suggesting that the absence of PGC-1a in the heart may, like the absence of STAT3, lead to prolactin-mediated antiangiogenic effects. Prolactin had no direct effects on PGC-1a or VEGF expression in cardiac cells, and prolactin levels did not differ in heart or serum between wild-type and HKO animals ( Supplementary  Fig. 4 ). These observations suggest that PGC-1a regulates two separate pro-angiogenic pathways in the heart-a VEGF pathway and a prolactin pathway-and that aberration of both pathways in PGC-1a HKO mice leads to PPCM (Fig. 4a ). To test this idea directly, both pathways were rescued simultaneously: breeding HKO mice were treated with daily subcutaneous injections of VEGF protein and with bromocriptine supplementation in the water (Fig. 4b ). This double treatment resulted in complete rescue of the PPCM in HKO females ARTICLE RESEARCH ( Fig. 4c ). After two pregnancies, heart weights and all echocardiographic indices of cardiac function (fractional shortening, LVEDD and LVESD) were normal in HKO mice ( Fig. 4c-h ). When only bromocriptine was used, some of the left ventricular dilation was prevented, but there was only minimal rescue of left ventricular function, showing that rescue of both pathways is necessary ( Fig. 4c-h) . Together, these data indicate that PPCM can be caused by an angiogenic imbalance and vascular dysfunction, at least in rodents.
Pre-eclampsia and cardiac dysfunction
To test the idea that anti-angiogenic signalling can cause cardiac dysfunction in pregnant women, we studied women with pre-eclampsia, in whom VEGF signalling is compromised owing to high serum levels of anti-angiogenic sFLT1 21 (see Supplementary Table 1 for patient characteristics). Cardiac function was evaluated non-invasively by measuring the myocardial performance index (MPI; also known as the Tei index) and other indices of cardiac function with cardiac echocardiography. MPI measures the relative duration of isovolaemic contraction and relaxation (Fig. 5a ), and is a sensitive marker of diastolic function [22] [23] [24] .Women with pre-eclampsia had markedly increased serum levels of sFLT1 ( Supplementary Fig. 5a , P 5 0.005), as previously shown 21 . Notably, women with pre-eclampsia also had a markedly abnormal MPI ( Fig. 5b and Supplementary Table 2 , P 5 0.01) and E/E9 ( Fig. 5c and Supplementary Table 2 , P 5 0.02), another sensitive measure of cardiac diastolic dysfunction that compares early diastolic mitral annulus (E9) and transmitral (E) flow velocities 25 . Moreover, the MPI correlated with levels of circulating sFLT1 (Fig. 5d , R 5 0.59, RESEARCH ARTICLE P 5 0.003). Elevated blood pressure in the pre-eclamptic women ( Supplementary Table 1 ) is unlikely to explain the worsening MPI, because MPI is thought to reflect cardiac function independently of blood pressure 22 , and pregnant women with similar mild elevations of blood pressure but without pre-eclampsia have normal cardiac function 26 . Instead, these data suggest that elevated sFLT1 causes the diastolic dysfunction. To test this idea directly, sFLT1 was delivered systemically to pregnant mice by intravenous injection of adenoviruses expressing sFLT1, and MPI was examined using high-resolution murine echocardiography. sFLT1 caused significant increases in MPI in these mice within 10 days (Fig. 5e ). These data, taken together with published observations in patients receiving anti-angiogenic therapies 10, 11 , strongly suggest that elevated sFLT1 causes cardiac dysfunction in women with pre-eclampsia. Although the left ventricular dysfunction recovers following delivery in many patients, a second insult in some women probably precipitates PPCM.
sFLT1 causes cardiomyopathy and is high in PPCM
The above observations strongly support the idea that PPCM can be induced by excess anti-angiogenic signalling, including the high expression of sFLT1 during late gestation seen both in women 27 and mice ( Supplementary Fig. 5c , P 5 0.009). To test this idea directly, sFLT1 was delivered systemically to nulliparous mice, as above. PGC-1a HKO mice that received sFLT1 developed profound cardiac failure within 3 weeks; these mice had increased cardiac weight and marked decreases in fractional shortening on echocardiography ( Fig. 6a-c) . This was accompanied by a marked drop in vascular density (Supplementary Fig. 6 ), although not in larger vessels ( Supplementary  Fig. 7 ). Wild-type mice also showed significant, though less extensive, decreases in vascular density and cardiac function after exposure to 3 weeks of sFLT1. Thus, sFLT1 alone is sufficient, even in the absence of pregnancy, to cause dramatic cardiomyopathy in the setting of a heart that is unable to withstand the anti-angiogenic insult.
To investigate further whether elevated sFLT1 levels in humans could be contributing to PPCM, plasma from women with PPCM was acquired 4-6 weeks post-partum and sFLT1 levels were measured. sFLT1 levels usually return to normal within 48-72 h after delivery 28 . sFLT1 levels were elevated in a large subset of these PPCM patients (P 5 0.002), remaining up to five-or tenfold higher than the levels in control participants (Fig. 6d ). Post-partum sFLT1 levels can remain slightly higher in subjects with pre-eclampsia 29, 30 , but the levels found here are notably higher. Thus, the findings are consistent with the idea that a substantial percentage of PPCM subjects have been exposed to pre-eclampsia, and that secretion of sFLT1 persists inappropriately post-partum. Indeed, in our own institution, 33% of the last 75 cases of PPCM were associated with pre-eclampsia ( Fig. 6e, f) , markedly more than the population rate of 3-5% (ref. 31 ). The persisting extra-placental source of sFLT1 in the post-partum period is not known, and may include placental remnants, circulating mononuclear cells 32 or shed syncytial microparticles 33 .
Discussion
Our study shows that angiogenic imbalance in the heart during the peri-partum period may lead to PPCM in mice and in humans. The data indicate that PPCM is caused by a 'two-hit' combination of, first, systemic anti-angiogenic signals during late pregnancy and, second, a host susceptibility marked by insufficient local pro-angiogenic defences in the heart. The first hit explains why PPCM is a disease of the late gestational period, which is precisely when circulating anti-angiogenic factors such as sFLT1 peak in pregnancy 21, 34 . Other pathways, such as prolactin or excess angiotensin II signalling, may also be involved 3, 35 . The first hit is also worse in pre-eclampsia, which is characterized by markedly elevated sFLT1 levels. Associations between pre-eclampsia and PPCM have been well documented in many populations 1, 2, [36] [37] [38] [39] [40] [41] (Supplementary Table 3 ). Interestingly, some studies involving women of African descent have not found an association between hypertensive disorders of pregnancy and PPCM 42 , suggesting that there is ethnic variability in the pathogenesis of PPCM. It is also possible that PPCM with and without associated pre-eclampsia have different pathogeneses 43 . Overall, our data suggest that elevated sFLT1 levels in pre-eclampsia contribute to at least the PPCM that is associated with pre-eclampsia. We further propose that elevated sFLT1 levels in fact present a challenge to the myocardium in all pregnancies, thus explaining why the peri-partum period puts women at risk of developing heart failure, even in the absence of pre-eclampsia. Interestingly, other situations of elevated sFLT1 (twin pregnancies) and recurrent exposures to sFLT1 (multiple pregnancies) are also strong risk factors for PPCM even in the absence of pre-eclampsia 2, 43, 44 .
Only a minority of women with pre-eclampsia develops PPCM, consistent with the existence of a second hit. Abnormal PGC-1a function is such an event in rodents, and it may also be a second hit in the case of humans. A number of previously identified processes may also constitute this second hit, including myocarditis, immune activation, viral infection and/or autoantibodies 43 . Interestingly, PGC-1a expression is repressed by inflammatory states in the heart and elsewhere 45, 46 , suggesting that many of the above processes that are implicated in PPCM may partly converge on PGC-1a. Consistent with this, we found repressed PGC-1a expression in cardiac samples from women with PPCM ( Supplementary Fig. 8 ). Abnormal STAT3 function and ROS production 3 and genetic predispositions 47 may also be contributing factors.
In conclusion, the data presented here support the idea that PPCM is partly a two-hit vascular disease due to imbalances in angiogenic signalling, and that anti-angiogenic states such as pre-eclampsia or multiple gestation substantially worsen the severity of the disease. Our data may explain why pregnancy triggers PPCM, and also the longstanding epidemiological observation that pre-eclampsia is a risk factor for developing PPCM. Pro-angiogenic therapies such as exogenous VEGF121, or removal of sFLT1 itself 48 , may therefore be beneficial in PPCM. 
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METHODS SUMMARY
All animal experiments were performed according to procedures approved by the Institutional Animal Care and Use Committee. Human soluble VEGF121 was a gift from Scios. Bromocriptine treatments were carried out as previously described 3 . Human studies were approved by the institutional review board of Beth Israel Deaconess Medical Center. Informed consent was obtained from all subjects. Angiogenic factor assays were performed with commercially available ELISA assays (R&D systems).
